These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 16466323)
1. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323 [TBL] [Abstract][Full Text] [Related]
2. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?]. Haberbosch W Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035 [TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
4. The rough road for rosiglitazone. Goldfine AB Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944 [TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Donnelly R Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791 [TBL] [Abstract][Full Text] [Related]
6. [Heart failure with thiazolidinedione treatment: what do we know today?]. Erdmann E Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858 [TBL] [Abstract][Full Text] [Related]
8. Metformin and pioglitazone: Effectively treating insulin resistance. Staels B Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073 [TBL] [Abstract][Full Text] [Related]
9. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control. Seufert J Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074 [TBL] [Abstract][Full Text] [Related]
10. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar? Krantz MJ Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430 [No Abstract] [Full Text] [Related]
11. Effects of pioglitazone on lipid and lipoprotein metabolism. Betteridge DJ Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057 [TBL] [Abstract][Full Text] [Related]
12. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Fonseca VA Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk and cardiometabolic protection: role of glitazones. Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866 [TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Krentz A Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860 [TBL] [Abstract][Full Text] [Related]
16. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Mazzone T Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043 [TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Patel RR Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087 [TBL] [Abstract][Full Text] [Related]
18. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Edelman SV Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701 [TBL] [Abstract][Full Text] [Related]
19. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Betteridge DJ Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248 [TBL] [Abstract][Full Text] [Related]